Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners
The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.
People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient and harder to use with the same accuracy.
About Author
More Stories
High-rise, high expectations: is Casablanca’s finance hub a model for African development?
Millions of Australian workers to get an above-inflation pay rise as minimum wage lifts by 3.5%
EU agrees to increase flight delay times before passengers get compensation